To explore the potential of timely screening using AI-assisted POCUS inference, we estimated that among all patients with hypertrophic cardiomyopathy (n=69) or transthyretin amyloid cardiomyopathy (n=48) who had at least one emergency department POCUS study in the YNHHS (before or after their diagnosis), 40 (58%) and 22 (46%) had a positive screen by POCUS any time before their eventual confirmatory imaging at the 90% sensitivity thresholds, respectively. The gene discussed is TTR; the disease is cardiac amyloidosis.